Cellular Therapy in NSCLC: Between Myth and Reality.
Adoptive cell therapies
CAR-T
Engineered adoptive cell therapies
NSCLC
TCR
Tumor-infiltrating lymphocytes (TILs)
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
26
06
2023
pubmed:
30
8
2023
medline:
30
8
2023
entrez:
30
8
2023
Statut:
ppublish
Résumé
In this paper, we review the current state and modalities of adoptive cell therapies (ACT) in non-small cell lung carcinoma (NSCLC). We also discuss the challenges hampering the use of ACT and the approaches to overcome these barriers. Several trials are ongoing investigating the three main modalities of T cell-based ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. The latter, in particular, has revolutionized the treatment of hematologic malignancies. However, the efficacy against solid tumor is still sparse. Major limitations include the following: severe toxicities, restricted infiltration and activation within the tumors, antigen escape and heterogeneity, and manufacturing issues. ACT is a promising tool to improve the outcome of metastatic NSCLC, but significant translational and clinical research is needed to improve its application and expand the use in NSCLC.
Identifiants
pubmed: 37646900
doi: 10.1007/s11912-023-01443-z
pii: 10.1007/s11912-023-01443-z
pmc: PMC10556121
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1161-1174Informations de copyright
© 2023. The Author(s).
Références
Hum Pathol. 2003 Jun;34(6):605-9
pubmed: 12827615
Mod Pathol. 2008 Jul;21(7):817-25
pubmed: 18469798
Clin Cancer Res. 2005 Nov 15;11(22):8055-62
pubmed: 16299236
Lung Cancer. 2003 Oct;42(1):23-33
pubmed: 14512184
Nat Immunol. 2020 Aug;21(8):914-926
pubmed: 32424363
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35086946
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
J Clin Oncol. 2023 Apr 10;41(11):1999-2006
pubmed: 36735893
Cancer Sci. 2007 Dec;98(12):1817-24
pubmed: 17888036
Nature. 2023 Apr;616(7957):534-542
pubmed: 37046095
Hum Gene Ther. 2002 Nov 1;13(16):1971-80
pubmed: 12427307
Cancer Immunol Res. 2019 Jun;7(6):910-922
pubmed: 31043415
Hum Immunol. 2000 Mar;61(3):334-40
pubmed: 10689125
Front Immunol. 2023 Mar 06;14:1140541
pubmed: 36949946
Cancer Res. 1992 Apr 1;52(7):1695-8
pubmed: 1312896
Cell Mol Immunol. 2021 Feb;18(2):427-439
pubmed: 32939032
Cancer Res. 2006 May 1;66(9):4922-8
pubmed: 16651449
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
Nat Biotechnol. 2019 Sep;37(9):1049-1058
pubmed: 31332324
Int J Cancer. 2012 Aug 15;131(4):844-54
pubmed: 21935923
Ann Oncol. 2021 Jan;32(1):120-121
pubmed: 33098996
J Immunother. 2004 May-Jun;27(3):184-90
pubmed: 15076135
Nat Commun. 2018 Dec 18;9(1):5361
pubmed: 30560866
Mol Ther. 2015 Jan;23(1):171-8
pubmed: 25142939
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33731480
Expert Opin Biol Ther. 2015;15(8):1145-54
pubmed: 25985798
Oncotarget. 2021 Dec 07;12(25):2449-2458
pubmed: 34917263
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322522
Cancer Cell. 2020 Apr 13;37(4):443-455
pubmed: 32289269
Nat Rev Cancer. 2019 Jul;19(7):392-404
pubmed: 31209264
J Clin Oncol. 2023 Apr 10;41(11):1992-1998
pubmed: 36809080
Am J Pathol. 2012 Dec;181(6):1903-10
pubmed: 23041612
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Int J Oncol. 2006 May;28(5):1089-98
pubmed: 16596224
Neuro Oncol. 2018 Mar 27;20(4):506-518
pubmed: 29016929
Mol Cancer Ther. 2021 Dec;20(12):2577-2584
pubmed: 34518295
Oncoimmunology. 2016 Apr 25;5(6):e1163462
pubmed: 27471638
J Cancer Res Clin Oncol. 2021 Dec;147(12):3725-3734
pubmed: 34032893
Sci China Life Sci. 2016 May;59(5):468-79
pubmed: 26968708
Nat Immunol. 2018 Dec;19(12):1352-1365
pubmed: 30420626
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Oncol Lett. 2018 Dec;16(6):6998-7007
pubmed: 30546433
Lancet Oncol. 2003 Jul;4(7):397-406
pubmed: 12850190
Clin Cancer Res. 2020 Oct 15;26(20):5368-5379
pubmed: 32873573
Nat Med. 2021 Aug;27(8):1410-1418
pubmed: 34385708
Pol J Pathol. 2022;73(1):1-5
pubmed: 35848474
Hum Gene Ther. 2009 Nov;20(11):1240-8
pubmed: 19702439
Blood. 2023 Feb 23;141(8):856-868
pubmed: 36416736
N Engl J Med. 2022 Dec 8;387(23):2113-2125
pubmed: 36477031
Lung Cancer. 2006 Aug;53(2):143-51
pubmed: 16782226
Front Immunol. 2018 Jun 26;9:1409
pubmed: 29997614
Cancer Res Treat. 2022 Oct;54(4):1005-1016
pubmed: 34856706
J Clin Invest. 2019 Jul 2;129(8):3464
pubmed: 31264975
Br J Cancer. 2002 May 6;86(9):1449-56
pubmed: 11986780
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546277
Clin Immunol. 2006 May;119(2):135-45
pubmed: 16458072
Cell Rep. 2018 May 15;23(7):2130-2141
pubmed: 29768210
Clin Cancer Res. 2015 Sep 15;21(18):4062-72
pubmed: 26059190
Int J Cancer. 2011 Sep 1;129(5):1137-48
pubmed: 21710496
Hum Gene Ther. 2012 Oct;23(10):1054-64
pubmed: 22734672
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
J Clin Oncol. 2021 Jul 20;39(21):2339-2349
pubmed: 33872070
Cancer Cell. 2022 May 9;40(5):479-493.e6
pubmed: 35452604
Mol Ther Oncolytics. 2018 Nov 06;11:127-137
pubmed: 30581986